Remission in early, aggressive rheumatoid arthritis: A multicentre prospective observational Italian study ARPA (Artrite reumatoide precoce Aggressiva)

Clinical and Experimental Rheumatology

Volumn 31, Issue 3, 2013, Pages 341-349

  Ceccarelli, F ^a   Perricone, C ^a   Trotta, F ^b   Cuomo, G ^c   Pellerito, R ^d   Bagnato, G ^e   Salaffi, F ^f   Caporali, R ^g   Cutolo, M ^h   Galeazzi, M ⁱ   Fiocco, U ^j   Lapadula, G ^k   Bombardieri, S ^l   Bianchi, G ^m   Gorla, R ⁿ   Giardina, A ^o   Gallo, G ^p   Giardino, A M ^p   Valesini, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d MAURIZIANO HOSPITAL   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

^f UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^g FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ UNIVERSITY HOSPITAL OF SIENA   (Italy)

^j UNIVERSITY OF PADOVA   (Italy)

^k UNIVERSITY OF BARI   (Italy)

^l UNIVERSITY HOSPITAL OF PISA   (Italy)

^m Ospedale La Colletta   (Italy)

ⁿ SPEDALI CIVILI   (Italy)

^o UNIVERSITY OF PALERMO   (Italy)

^p Labor Srl   (Italy)

more..

Author keywords

Anti TNF; DMARDs; Remission; Rheumatoid arthritis

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DISEASE PROGRESSION; EARLY MEDICAL INTERVENTION; FEMALE; HUMANS; ITALY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878353431     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. PERRICONE C, CECCARELLI F, VALESINI G: An overview on the genetic of rheumatoid arthritis: a never-ending story. Autoimmun Rev 2011; 10: 599-608.
2. WOLFE F, HAWLEY DJ: The longterm outcomes of rheumatoid arthritis: Work disability: a prospective 18 year study of 823 patients. J Rheumatol 1998; 25: 2108-17.
3. YELIN E, WANKE LA: An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999; 42: 1209-18.
4. WOLFE F, MITCHELL DM, SIBLEY JT et al.: The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-94.
5. HARAOUI B, POPE J: Treatment of early rheumatoid arthritis: concepts in management. Semin Arthritis Rheum 2011; 40: 371-88.
6. GRIGOR C, CAPELL H, STIRLING A et al.: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263-9.
7. ANDERSON PJ: Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005; 34: 19-22.
8. HANNONEN P, MOTTONEN T, HAKOLA M, OKA M: Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993; 36: 1501-9.
9. MCQUEEN FM, BENTON N, CRABBE J et al.: What is the fate of erosions in early rheumatoid arthritis? Tracking individual lesions using x rays and magnetic resonance imaging over the first two years of disease. Ann Rheum Dis 2001; 60: 859-68.
10. SYMMONS D, TRICKER K, HARRISON M et al.: Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs - results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial. Rheumatology (Oxford) 2006; 45: 558-65.
11. KNEVEL R, SCHOELS M, HUIZINGA TW et al.: Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 987-94.
12. RANTALAIHO V, KORPELA M, HANNONEN P et al.: The good initial response to therapy with a combination of traditional diseasemodifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 2009; 60: 1222-31.
13. BOERS M, VERHOEVEN AC, MARKUSSE HM et al.: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18.
14. O'DELL JR, HAIRE CE, ERIKSON N et al.: Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 1287-91.
15. DOUGADOS M, COMBE B, CANTAGREL A et al.: Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999; 58: 220-5.
16. WOLFE F, HAWLEY DJ: Remission in rheumatoid arthritis. J Rheumatol 1985; 12: 245- 52.
17. SOKKA T, MAKINEN H: Remission makes its way to rheumatology. Arthritis Res Ther 2010; 12; 129.
18. BREEDVELD FC, WEISMAN MH, KAVANAUGH AF et al.: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.
19. VAN DER BIJL AE, GOEKOOP-RUITERMAN YP, DE VRIES-BOUWSTRA JK et al.: Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2007; 56: 2129-34.
20. EMERY P, BREEDVELD FC, HALL S et al.: Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372: 375-82.
21. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
22. PREVOO ML, VAN 'T HOF MA, KUPER HH, VAN LEEUWEN MA, VAN DE PUTTE LB, VAN RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
23. FRANSEN J, VAN RIEL PL: The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005; 23 (Suppl. 39): S93-9.
24. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
25. ST CLAIR EW, VAN DER HEIJDE DM, SMOLEN JS et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-43.
26. LEE DM, WEINBLATT ME: Rheumatoid arthritis. Lancet 2001; 358: 903-11.
27. SOKKA T, HÄKKINEN A: Poor physical fitness and performance as predictors of mortality in normal populations and patients with rheumatic and other diseases. Clin Exp Rheumatol 2008; 26 (Suppl. 51): S14-20.
28. VAN DER HEIJDE DM, VAN LEEUWEN MA, VAN RIEL PL, VAN DE PUTTE LB: Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 1995; 22: 1792-6.
29. LINDQVIST E, JONSSON K, SAXNE T, EBERHARDT K: Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis 2003; 62: 611- 6.
30. O'DELL JR, LEFF R, PAULSEN G et al.: Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1164-70.
31. PINCUS T, O'DELL JR, KREMER JM: Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med 1999; 131: 768-74.
32. SMOLEN JS, LANDEWE R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
33. NELL VP, MACHOLD KP, EBERL G, STAMM TA, UFFMANN M, SMOLEN JS: Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 906-14.
34. LARD LR, VISSER H, SPEYER I et al.: Early versus delayed treatment in patients with recent- onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111: 446-51.
35. VERSTAPPEN SM, JACOBS JW, VAN DER VEEN MJ et al.: Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 1443-9.
36. FURST DE: Development of TNF inhibitortherapies for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2010; 28 (Suppl. 59): S5-12.
37. EMERY P, FLEISCHMANN RM, MORELAND LW et al.: Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, doubleblind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009; 60: 2272-83.
38. MIERAU M, SCHOELS M, GONDA G, FUCHS J, ALETAHA D, SMOLEN JS: Assessing remission in clinical practice. Rheumatology (Oxford) 2007; 46: 975-9.
39. SOKKA T, HETLAND ML, MAKINEN H et al.: Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum 2008; 58: 2642-51.
40. SMOLEN JS, ALETAHA D, BIJLSMA JW et al.: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
41. SHAHOURI SH, MICHAUD K, MIKULS TR et al.: Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. Arthritis Rheum 2011; 63: 3204-15.
42. HYRICH KL, WATSON KD, LUNT M, SYMMONS DP: Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford) 2011; 50: 117-23.
43. FURST DE, PANGAN AL, HARROLD LR et al.: Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res (Hoboken) 2011; 63: 856-64.
44. LIE E, VAN DER HEIJDE D, UHLIG T et al.: Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NORDMARD register. Ann Rheum Dis 2011; 70: 2103-10.
45. DESCALZO MÁ, CARBONELL J, GONZÁLEZÁlvaro I et al.: Effectiveness of a clinical practice intervention in early rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 321-30.